Value of Physical Capacity Tests in Lung Cancer

NCT01943578 | Completed DMC

• 1 other identifier: 2007-58-0015-30-1059
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The study examines the physical capacity of lung cancer patients assessed with the six minute walk test and handgrip strength. Demographic and selfreported exercise behavior is registered to explore correlations to functional and physical capacity. Assessments are made before first chemotherapy cycle and after fourth chemotherapy cycle, an expected average of 12 weeks between first and second assessment.

Conditions

Non Small Cell Lung Cancer; Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Mortality - Survival time

  Prognostic value of the six minute walk and handgrip strength on mortality

  time from first chemotherapy treatment to death, assessed after 30 months

Secondary Outcomes (3)

• Hand grip strength

  before first chemotherapy and after fourth cycle of chemotherapy, an expected average of 12 weeks between first and second assessment.

• Self reported exercise behavior

  before first chemotherapy and after fourth cycle of chemotherapy, an expected average of 12 weeks between first and second assessment.

• Six minute walk test

  Before first and after fourth chemotheraphy cycle, an expected average of 12 weeks between first and second assessment.

Other Outcomes (1)

• FACT-L

  Before first chemotherapy and after fourth cycle of chemotherapy, an expected average of 12 weeks between first and second assessment.

Study Arms (1)

lung cancer patients

Non Small Cell Lung Cancer, Small Cell Lung Cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Non Small Cell Lung Cancer Stage Small Cell Lung Cancer

You may qualify if:

• Non small cell lung cancer stage I-IV
• Small cell lung cancer
• Patients \>18 years
• WHO performance status 0-2
• undergoing chemotherapy

You may not qualify if:

• unstable angina during the previous month
• myocardial infarction diagnosed within the last month
• not approval for physical activity by primary oncologist
• inability to provide informed consent.

Sponsors & Collaborators

• Rigshospitalet, Denmark: lead

Study Sites (1)

University Hospital of Copenhagen

Copenhagen, 2200, Denmark

Location

Related Links

• Related Info

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Seppo Langer, Phd.

  University Hospital of Copenhagen, Rigshospitalet

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: phd student

Study Record Dates

• First Submitted: August 30, 2013
• First Posted: September 17, 2013
• Study Start: September 1, 2013
• Primary Completion: June 1, 2014
• Study Completion: June 1, 2014
• Last Updated: November 5, 2014

Record last verified: 2014-11

Locations

DK (1)